Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 195

1.

[Biological markers in the diagnosis of dementia and Alzheimer's disease].

Meiner Z, Rosenmann H.

Harefuah. 2012 May;151(5):289-93, 318. Review. Hebrew.

PMID:
22844733
2.

New developments in the diagnosis of dementia.

Eschweiler GW, Leyhe T, Klöppel S, Hüll M.

Dtsch Arztebl Int. 2010 Oct;107(39):677-83. doi: 10.3238/arztebl.2010.0677. Epub 2010 Oct 1. Review.

3.

Dementia mimicking Alzheimer's disease Owing to a tau mutation: CSF and PET findings.

Tolboom N, Koedam EL, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YA, Lammertsma AA, Scheltens P, van Berckel BN.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):303-7. doi: 10.1097/WAD.0b013e3181cf35ec.

PMID:
20683187
4.

Value of neuropsychological tests, neuroimaging, and biomarkers for diagnosing Alzheimer's disease in younger and older age cohorts.

Schmand B, Eikelenboom P, van Gool WA; Alzheimer's Disease Neuroimaging Initiative.

J Am Geriatr Soc. 2011 Sep;59(9):1705-10. doi: 10.1111/j.1532-5415.2011.03539.x. Epub 2011 Aug 24.

PMID:
21883100
5.

MRI and CSF studies in the early diagnosis of Alzheimer's disease.

de Leon MJ, DeSanti S, Zinkowski R, Mehta PD, Pratico D, Segal S, Clark C, Kerkman D, DeBernardis J, Li J, Lair L, Reisberg B, Tsui W, Rusinek H.

J Intern Med. 2004 Sep;256(3):205-23.

6.

Magnetic resonance and PET studies in the early diagnosis of Alzheimer's disease.

Mosconi L, De Santi S, Rusinek H, Convit A, de Leon MJ.

Expert Rev Neurother. 2004 Sep;4(5):831-49. Review.

PMID:
15853510
7.

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

Marksteiner J, Hinterhuber H, Humpel C.

Drugs Today (Barc). 2007 Jun;43(6):423-31. Review.

PMID:
17612711
8.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
9.

Biomarkers in the diagnosis of Alzheimer's disease: are we ready?

Sunderland T, Hampel H, Takeda M, Putnam KT, Cohen RM.

J Geriatr Psychiatry Neurol. 2006 Sep;19(3):172-9. Review.

PMID:
16880359
11.

[Diagnosis without therapy: early diagnosis of Alzheimer's disease in the stage of mild cognitive impairment].

Gertz HJ, Kurz A.

Nervenarzt. 2011 Sep;82(9):1151-9. doi: 10.1007/s00115-010-3213-3. Review. German.

PMID:
21221517
12.

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.

Chételat G, Villemagne VL, Pike KE, Ellis KA, Bourgeat P, Jones G, O'Keefe GJ, Salvado O, Szoeke C, Martins RN, Ames D, Masters CL, Rowe CC; Australian Imaging Biomarkers and Lifestyle Study of ageing (AIBL) Research Group.

Brain. 2011 Mar;134(Pt 3):798-807. doi: 10.1093/brain/awq383. Epub 2011 Feb 9.

13.

CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.

Bibl M, Mollenhauer B, Esselmann H, Lewczuk P, Klafki HW, Sparbier K, Smirnov A, Cepek L, Trenkwalder C, Rüther E, Kornhuber J, Otto M, Wiltfang J.

Brain. 2006 May;129(Pt 5):1177-87. Epub 2006 Apr 6.

14.

Cerebrospinal fluid biomarker results in relation to neuropathological dementia diagnoses.

Brunnström H, Rawshani N, Zetterberg H, Blennow K, Minthon L, Passant U, Englund E.

Alzheimers Dement. 2010 Mar;6(2):104-9. doi: 10.1016/j.jalz.2009.12.005.

PMID:
20298970
15.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
16.

The dynamic marker hypothesis of Alzheimer's disease and its implications for clinical imaging.

Cavedo E, Frisoni GB.

Q J Nucl Med Mol Imaging. 2011 Jun;55(3):237-49. Review.

PMID:
21532538
17.

Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.

Schmand B, Huizenga HM, van Gool WA.

Psychol Med. 2010 Jan;40(1):135-45. doi: 10.1017/S0033291709991516. Epub 2009 Oct 29.

PMID:
19863841
19.

A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic.

Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M.

Dement Geriatr Cogn Disord. 2010;30(4):285-92. doi: 10.1159/000320265. Epub 2010 Sep 22.

PMID:
20861634
20.

The role of MRI and PET/SPECT in Alzheimer's disease.

Coimbra A, Williams DS, Hostetler ED.

Curr Top Med Chem. 2006;6(6):629-47. Review.

PMID:
16712496
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk